Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer

NCT05607004 is registered in ClinicalTrials.gov with Atossa Therapeutics, Inc. as lead sponsor.

NCT NCT05607004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer
Lead sponsor
Atossa Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 14, 2023
Completion date
April 30, 2027
Enrollment
87 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, estrogen-receptor-positive breast cancer, her2-negative breast cancer, invasive breast cancer